Bruker’s Growth Potential Driven by Innovations and Strategic Cost Management

Jefferies analyst Tycho Peterson has maintained their bullish stance on BRKR stock, giving a Buy rating on June 3.

Tycho Peterson has given his Buy rating due to a combination of factors that suggest strong potential for Bruker’s growth. The company’s recent innovations, particularly in mass spectrometry with the timsOMNI and timsMetabo systems, have significantly expanded their addressable market. These advancements are expected to drive substantial interest and adoption, especially within the pharmaceutical sector and international markets like China, which could lead to meaningful revenue growth.
Additionally, Bruker’s strategic cost management initiatives, including labor flexibility in Europe and R&D rationalization, are anticipated to enhance margins significantly. Despite some challenges in the U.S. market, the outlook remains optimistic due to positive trends in European funding and the potential upside from Chinese stimulus measures. These factors collectively underpin Peterson’s confidence in Bruker’s ability to achieve sustainable growth and justify the Buy rating.

In another report released on June 3, Bank of America Securities also maintained a Buy rating on the stock with a $61.00 price target.

BRKR’s price has also changed moderately for the past six months – from $59.500 to $37.830, which is a -36.42% drop .